Clinical Research Progress in Nimotuzumab Combination with Radiotherapy

Epidermal growth factor receptor(EGFR) has overexpressed in many tumors,associating with tumor progression and resistances to radiation and chemotherapy. Inhibition of EGFR signaling pathway can control tumor development. Nimotuzumab is a new kind of EGFR monoclonal antibody,has been applied in a variety of malignant tumors. The relevant clinical researches about nimotuzumab combined radiotherapy are reviewed in this article.